Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
3(100.0%)
3Total
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07472075Phase 2Recruiting

Melatonin Versus Placebo for Bipolar Disorder

Role: lead

NCT05035316Phase 2Completed

Effects of Low Dose Aspirin in Bipolar Disorder (The A-Bipolar RCT)

Role: lead

NCT03315897Phase 2Completed

Effects of Erythropoietin on Cognition and Neural Activity in Mood Disorders

Role: lead

All 3 trials loaded